Agencourt® Receives Contract for National Cancer Institute's Office of Cancer Genomics
News Nov 14, 2007
Under the agreement, NCI will supply Agencourt with normal and cancer tumor tissue samples and periodic lists of genes and targeted regions to be sequenced.
The goal of the project is to provide NCI research collaborators with a consistent, cost-effective, high-throughput sequencing resource. NCI collaborators who are working on cancer genomics research may request the sequencing of specific genes at any time. The initial term of the contract is one year, with an option to renew for a second year.
Collaborators will submit sequence trace data to the National Center for Biotechnology information (NCBI) and the base calls will be placed in a database managed by the NCI.
Agencourt will also develop a special web site that is accessible by project collaborators. This web site, with the posted information, will allow NCI collaborators to query the NCBI Trace database for additional metadata and relate it to other experimental results and clinical data by bio-specimen ID.
The project has been funded in whole or in part with federal funds from the National Cancer Institute.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.